
Understanding Genetic Tests and How They Are Used

David Flannery,MD Medical Director American College of Medical Genetics and Genomics



Starting Points


• Genes are made of DNA and are carried on chromosomes





• Genetic disorders are the result of alteration of genetic material

 These changes may or may not be inherited



(A) Chromosomal mutations involve breaks in a chromosome. (B) Point mutations occur when one nitrogenous base is substituted for another - in this case, T becomes G. (C) Expansions occur when the number of copies of a codon is repeated. The expansion shown here involves CAG, just like the expansions in HD. However, expansions in HD can be much larger than the 2 extra copies of CAG shown here.

Objectives

- To explain what variety of genetic tests are now available
- What these tests entail
- What the different tests can detect
- How to decide which test(s) is appropriate for a given clinical situation



Types of Genetic Tests


Cytogenetic

(Chromosomes)

DNA

Metabolic


(Biochemical)






Chromosome Test (Karyotype)

Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display.



How a Chromosome test is Performed




Medicaldictionary.com



Use of Karyotype

http://medgen.genetics.utah.e du/photographs/diseases/high /peri001.jpg



Karyotype Detects Various Chromosome Abnormalities

- Aneuploidy- to many or to few chromosomes

 Trisomy, Monosomy, etc.
- Deletions missing part of a chromosome
 Partial monosomy
- Duplications extra parts of chromosomes
 - Partial trisomy
- Translocations
 - Balanced or unbalanced

Karyotyping has its Limits

- Many deletions or duplications that are clinically significant are not visible on high-resolution karyotyping
- These are called "microdeletions" or "microduplications"

Microdeletions or microduplications are detected by FISH test


• <u>Fluorescence</u> In <u>situ</u> <u>Hybridization</u>



FISH


fluorescent in situ hybridization: (FISH) A technique used to identify the presence of specific chromosomes or chromosomal regions through hybridization (attachment) of fluorescently-labeled DNA probes to denatured chromosomal DNA.

Step 1. Preparation of probe. A probe is a fluorescently-labeled segment of DNA comlementary to a chromosomal region of interest.



Step 2. Hybridization. Denatured chromosomes fixed on a microscope slide are exposed to the fluorescently-labeled probe. Hybridization (attachment) occurs between the probe and complementary (i.e., matching)


chromosomal DNA.



Genereviews.org

FISH for DiGeorge/Velocardiofacial syndrome

deleted for DiGeorge chromosome region (DGCR)



FISH detects small (submicroscopic) chromosome

Deletions

- 15q11.2 deletion in Prader-Willi syndrome and Angelman syndrome
- 22q11.2 deletion in velocardiofacial syndrome

Duplications

- *PMP22* CMT1A
- *PLP1* Pelizeus-Merzbacher syndrome


Other Uses of FISH

- Interphase FISH for rapid diagnosis of Trisomies
- Example: Newborn with severe congenital heart disease and facial and hand anomalies.
- If it is Trisomy 18, the prognosis for survival to age 1 year is extremely poor, and cardiac surgery will be very risky
- Karyotype take 72 hours



- Interphase FISH
- Done on a blood sample
- Takes a few hours to get results

• 3 signals for chromosome 18



A Patient Who Needs Genetic Testing

- Boy who has:
 - Microcephaly
 - Hyperactivity
 - Seizures
 - Developmental delay
 - Verbal apraxia
 - Happy affect

Doctor is concerned that child may have Angelman Syndrome

- ~68% of cases have a microdeletion of a region of Chromosome 15
- So the first test to order would be FISH with a specific DNA probe that detects this region

Result of the FISH test

- "NO DELETION was detected in the Angelman syndrome critical region of chromosome 15 using FISH. [ish 15q11.2(D15S10x2)]
- What next?
- ~11% of cases are caused by mutation in the UBE3A gene
- 7% have Uniparental Disomy
- 3% have an Imprinting Center defect


Sequence Analysis

Step 1: Amplification.


The segment of DNA to be sequenced is PCR-amplified using normal nucleotides (i.e., dATP, dTTP, Α. dGTP, and dCTP) and fluorescently labeled, dideoxy nucleotides (i.e., ddATP, ddTTP, ddGTP, ddCTP). (Dideoxy nulceotides arrest chain elongation.)




В. The DNA segment is copied when normal nucleotides are incorporated. Copying ceases when a dideoxy nucleotide is incorporated. By this process, many different-sized fluorescently labeled DNA fragments are produced.



Step 2: Sequence determination. The fragments are sorted by length. A sequencing machine reads the fluorescent wavelengths to determine which nucleotide is at the end of each fragment.



Step 3: Sequence reporting. Sequence data are typically displayed on an electropherogram as colored peaks. Each peak represents a nucleotide, corresponding to the letter above it.



	Rec
	Gree
\land	Blue
	Blac

Electri

opherogram	
------------	--


Red	Т
Green	A
Blue	C
Black	G

Wavelength Nucleotide

Genereviews.org



Result of Sequencing UBE3A Gene



DeMolfetta, et al.BMC Med Genet. 2012; 13: 124.

Sequencing Results Can be Complex

 ACMG and AMP Joint Policy Statement: "Standards and guidelines for the interpretation of sequence variants" (2015)

- Pathogenic
- Likely Pathogenic
- Benign
- Likely Benign
- Uncertain Significance

Possible explanations for a false negative test result if a sequence change is not detected

- Patient does not have a change in the tested gene but there is another gene that also produces the phenotype
- Patient has a sequence change that cannot be detected by sequence analysis (e.g., a large deletion)
- Patient has a sequence change in a region of the gene (e.g., an intron or regulatory region) not covered by this laboratory's test



Another Useful Test

Chromosome microarray


What is Chromosome Microarray?

- A gene chip which uses Comparative Genomic Hybridization to detect missing regions of chromosomes or extra segments of chromosomes
- Essentially it is performing thousands of FISH tests simultaneously

What is a Microarray?

Understanding CGH Technology

Short segments of DNA (such as bacterial artificial chromosomes, BACs) containing regions of interest are printed onto a glass slide.






Chromosome Microarray on a Gene Chip

- The probes attached to the gene chip are unique segments of every chromosome
- Depending on the number of probes, it could represent every genetic region of the entire genome



Microarray: Hybridization


Labelled cDNA A



Labelled mRNA hybridise to corresponding probe

Signature Genomics






C does not stick to another C, so no match is made



Microarray: Measurement

Genes not expressed in the source tissue

A gene expressed in the source tissue



Comparative Genomic Hybridization

- DNA from subject tissue and from normal control tissue (reference) is labeled with different colors.
- After mixing subject and reference DNA the mix is hybridized to a slide containing hundreds or thousands of defined DNA probes.
- The The fluorescence color ratio at each probe location on the array is used to evaluate regions of DNA gain or loss in the subject sample.

Microarray can detect

- Duplicated genomic material
- Deleted genomic material
- Multiple deletions and or duplications of genomic regions



Microarray cannot

 Determine if deletion or duplication is due to a Chromosome Translocation

Microarray Results

- Microarray makes 10-15% more diagnoses than karyotyping in the evaluation of patients with Idiopathic Learning disability
- Some studies report as high as 28% diagnosis rate with microarray
- ACMG Practice Guideline 2010 affirming use of Chromosome Microarray as a first-tier genetic test in evaluating patients with intellectual disability and/or multiple congenital anomalies

Clinical Utility of Chromosome Microarray

(i)			
Contract Cont	(−))	🕃 http://www.ncbi.nlm. nih.gov /pmc/articles/PMC4538218/ 🔎 🐨 🖉 🖉 🕼 🖉 🖓 🖓 🖓 🖓 🖓 🖓 🖓 🖓 🖓 🖓 🖓 🖓 🖓	↑ ★ ⅔
Image: Note Note Service Servic	<u>F</u> ile <u>E</u> dit		
PMC	× 🥝 -		
With the limits of white Initis & dvanced journalist journalist the limits dvanced journalist <td></td> <td>Sign in to NCBI Resources 🛛 How To 🖸</td> <td>^</td>		Sign in to NCBI Resources 🛛 How To 🖸	^
With the limits of white Initis & dvanced journalist journalist the limits dvanced journalist <td></td> <td></td> <td></td>			
Total List > MPO Open Access > PMC4538215		US National Library of Medicine	
Conception Conception<		National Institutes of Health Limits Advanced Journal list neip	
Robin Z Hayeems, 12* Ny Hoang, 3.4 Sebastien Chenier, ⁵ Dimitri J Stavropoulos, ⁶ Shuye Pu, ⁷ Rosanna Weksberg, 3.4.8ª Author information ▶ Article notes ▶ Copyright and License information ▶ Author information ▶ Article notes ▶ Copyright and License information ▶ Author information of pediatric chromosome microarray (CMA) results presents diagnostic and medical management challenges. Understanding management practices triggered by CMA will inform clinical utility and resource planning. Using a retrospective cohort design, we extracted clinical and management related data from the records of 752 children with congenital anomalies and/or developmental delay who underwent CMA in an academic pediatric genetics clinic (2009–2011). Frequency distributions and relative met the met thile mer with reportable and benign CMA results rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results review and met [Ultrasound Obstet Gynecol. 2013] Additional information from chromosomal microarray analysis (CMA) over conventional karyotyping when diagnosi (BJOG. 2014]		PubReader format: click here to try PubReader format: click here to try Formats: Article PubReader ePub (beta) PDF (462K) Citation Eur J Hum Genet. 2015 Sep; 23(9): 1135–1141. Published online 2014 Dec 10. doi: 10.1038/elhg.2014.260 PMCID: PMC4538218 Share F Facebook Twitter Songle+	
Robin Z Hayeems, ^{1,2} . ^N W Hoang, ^{3,4} Sebastien Chenier, ⁵ Dimitri J Stavropoulos, ⁶ Shuye Pu, ⁷ Rosanna Weksberg, ^{3,4,8} and <u>Cheryl Shuman</u> ^{3,4,8} Author information ► Article notes ► Copyright and License information ► Author information ► Article notes ► Copyright and License information ► Abstract Co to: ✓ Interpretation of pediatric chromosome microarray (CMA) results presents diagnostic and medical management challenges. Understanding management practices triggered by CMA will inform clinical utility and resource planning. Using a retrospective cohort design, we extracted clinical and management-related data from the records of 752 children with congenital anomalies and/or developmental delay who underwent CMA in an academic pediatric genetics clinic (2009–2011). Frequency distributions and relative rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results (CMA) over conventional karyotyping when diagnosi [BJOG. 2014]		following pediatric microarray	
Abstract Go to: Abstra		Robin Z Hayeems, ^{1,2} Ny Hoang, ^{3,4} Sebastien Chenier, ⁵ Dimitri J Stavropoulos, ⁶ Shuye Pu, ⁷ Rosanna Weksberg, ^{3,4,8,9} Add to Favorites	
Abstract Go to: Abstra		O <u>Author information ►</u> Article notes ► Copyright and License information ►	
Interpretation of pediatric chromosome microarray (CMA) results presents diagnostic and medical management challenges. Understanding management practices triggered by CMA will inform clinical utility and resource planning. Using a retrospective cohort design, we extracted clinical and management- related data from the records of 752 children with congenital anomalies and/or developmental delay who underwent CMA in an academic pediatric genetics clinic (2009–2011). Frequency distributions and relative rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results rates (RR) of post-CMA medical recommendations in children with reportable may be neith the marth the		Abstract Similar articles in PubMed	
management challenges. Understanding management practices triggered by CMA will inform clinical utility and resource planning. Using a retrospective cohort design, we extracted clinical and management related data from the records of 752 children with congenital anomalies and/or developmental delay who underwent CMA in an academic pediatric genetics clinic (2009–2011). Frequency distributions and relative rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results		Interpretation of pediatric chromosome microarray (CMA) results presents diagnostic and medical [Genet Med. 2011]	
related data from the records of 752 children with congenital anomalies and/or developmental delay who underwent CMA in an academic pediatric genetics clinic (2009–2011). Frequency distributions and relative rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results results are academic anomalies and/or developmental delay who		management challenges. Understanding management practices triggered by CMA will inform clinical The clinical impact of chromosomal microarray on paediatric care	
rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results (CMA) over conventional karyotyping when diagnosi [BJOG. 2014]		related data from the records of 752 children with congenital anomalies and/or developmental delay who use of prenatal chromosomal microarray: prospective cohort study and systematic review and met. [Ultrasound Obstet Gynecol. 2013]	
		Additional mormation from chromosomal microarray analysis	
		were calculated. Medical recommendations were provided for 79.6% of children with reportable results and See reviews	~

Possible Results from a Chromosome Microarray Test

- A <u>normal result</u> means that no duplications or deletions of genetic material were found.
- A <u>likely pathogenic result</u> means that a duplication or deletion of genetic material was found, and this is likely to cause health or learning problems. Your doctor might be able to make predictions on how this genetic change will affect a person.
- A <u>likely benign result</u> means that a genetic change was found, but it **is not** likely to cause health or learning problems. Every person has slight differences in his or her genes. These differences make each person individual and unique. Benign changes (duplications or deletions that do not cause learning or health problems) are part of normal human variation.

Possible Results from a Chromosome Microarray Test(continued)

- A <u>variant of unknown significance</u> is a genetic change that has not been reported before in other individuals. It is unclear whether the genetic change might cause learning or health problems, or if it is **benign**.
- When a <u>variant of unknown significance</u> is found on microarray, the lab recommends testing the parents to see if either of them has the same genetic change.
 - If either parent is found to have the same genetic change and has no learning or health concerns, then the variant is more likely to be benign.
 - If the parents are **not** found to have the same genetic change, it is still difficult to tell whether the change is normal human variation or if it could cause any health or learning problems. In these cases, we watch to see if any other individuals are reported with a similar genetic difference. Over time we may learn more about what this change means.



What other types of microarrays?


• "SNiP" array

Single Nucleotide Polymorphisms ("SNiPs")

• A Single Nucleotide Polymorphism (SNP) is the variation of a single base pair in the DNA sequence between either the members of a species or between the paired chromosomes of an individual.



SNP



- Here there is a single nucleotide difference in the sequence of part of a gene between these 2 individuals:
 - Individual 1 has TTCCCTACCAC
 - Individual 2 has TTCCTTACCAC
- This change doesn't necessarily change the function of the gene

Genereviews.org

SNiP Arrays

- Currently have 1.8 million probes for SNiPs
- If the tested DNA matches the sequence of a specific SNiP in a specific gene = positive result
- Like chromosome microarrays, can also detect small deletions or duplications
- But,
- Can also yield surprising information beyond deletion or duplication of genomic regions
 - "Loss of Heterozygosity"

Identification of incestuous parental relationships by SNP-based DNA microarrays


CP Schaaf, DA Scott, J Wiszniewska and AL Beaudet


The Lancet Volume 377, Issue 9765, Pages 555-556 (February 2011) DOI: 10.1016/S0140-6736(11)60201-8



Copyright © 2011 Elsevier Ltd Terms and Conditions







Source: The Lancet 2011; 377:555-556 (DOI:10.1016/S0140-6736(11)60201-8)

Terms and Conditions

Case I saw Back in Georgia

- Internationally adopted girl with MR, non-specific facies, no family or pre-natal history available
- Karyotype, Chromosome microarray, DNA tests for MECP2, Angelman syndrome, all negative
- SNiP array showed high degree of loss of heterozygosity
 - Corresponding to biologic parents being closely related, and thus the girl must have some sort of autosomal recessive disorder

Another Case

- Girl with complex phenotype, with MR, nonspecific dysmorphism, multiple congenital anomalies, endocrine dysfunction
- Extensive work-up has been negative
- SNiP array showed areas of loss-ofheterozygosity
 - one of the areas has gene for Bardet-Biedl syndrome type
 7
 - Patient has a few features compatible with BBS, but lacks many of the most characteristic features (pigmentary retinal dystrophy, polydactyly,renal malformation) but we are proceeding with sequencing the BBS7 gene

Let's Turn to Another Patient Situation

- 3 year old boy who is not walking and has only a few word vocabulary
- Growth is normal
- He has a long facial profile
- Family history is not contributory
- First test to evaluate the underlying cause?

Chromosome Microarray

- Normal
- What next?
- The most common cause of intellectual disability in males is Fragile-X syndrome,
- So Dr. sends blood for Fragile-X testing

CpG island methylated in full mutation

> CGG repeat

region

AUG

Fragile X syndrome is produced when the protein product of FMR1 is reduced or missing. Expansion of the CGG repeat to >230 repeat copies is accompanied by abnormal methylation of the CpG island. Methylation of the CpG island may result in no transcription of FMR1.

12

-13

9

10

11

Molecular Diagnosis - Most Commonly Used Technique

14

15

16


17

Triplet Repeat Primed PCR: uses 3 PCR primers, two that flank the repeat section and a third located within the repeat segment.

Most common alleles = 29 or 30 repeats

Courtesy of J Tarleton, PhD

Triplet Repeat Primed Polymerase Chain Reaction



Chen, et al 2010 J Mol Diag 12: 589

J Tarleton, PhD



Southern blot analysis

Older technology but still occasionally useful to resolve the myriad of molecular rearrangements that occur in FMR1

CH₃ site



2.8 kb

StB12.3

J Tarleton, PhD

Eco

Patient results

- 330 CGG repeats
- Mom needs to be tested because the risk of having another affected male increases depending on how many repeats she has
- AND
- Her father should be tested because he may have a pre-mutation expansion, which places him at risk for developing Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) as he ages

Examples of Other Trinucleotide Repeat Disorders

- Huntington Disease
- Spinocerebellar Ataxias
- Myotonic Dystrophy

THANK YOU

..... 0000